FDA authorises first direct-to-consumer test for BRCA mutations, with caveats
March 6, 2018Research and Development, Sales and Marketing 23andME, BRCA, Cancer, FDA, breast cancer, ovarian cancer, pharma
The FDA has given its authorisation to the first ever direct-to-consumer (DTC) test to identify three BRCA gene mutations which …
Blood test could predict treatment effectiveness months earlier in breast cancer
March 6, 2018Manufacturing and Production, Research and Development Cancer, ICR, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, breast cancer, palbociclib, pharma
A team of scientists at The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust have …
Switching to Gilead’s Biktarvy proves non-inferior in HIV patients
March 6, 2018Manufacturing and Production, Research and Development Biktarvy, Gilead, HIV, pharma
Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir …
University of Adelaide is fighting antibiotic-resistant superbugs by starving them of iron
March 6, 2018Manufacturing and Production, Research and Development Adelaide, Australia, Superbugs, antibiotic resistance, pharma
A team of researchers from Australia’s University of Adelaide have developed a new method to fighting antibiotic-resistant bacteria by starving …
Martin Shkreli ordered to forfeit $7.36m ahead of fraud sentencing
March 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Martin Shkreli, pharma
Reviled pharma bro Martin Shkreli is experiencing another heavy dose of karma after a US judge ordered him to forfeit …
Dermira terminates acne drug after Phase 3 failure, wiping $667m from market value
March 5, 2018Manufacturing and Production, Research and Development Dermira, acne, pharma, trial failure
Skin specialist biopharma firm Dermira has seen its stock crash and burn following the announcement that it plans to terminate …
Uncovering trends in the future of real world data
March 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, feature, pharma, real world data, real world evidence
A new report has canvassed the intentions of industry players in the use of real world data and evidence over …
Gilead investigational data gives hope for HIV eradication in humans
March 5, 2018Research and Development, Sales and Marketing Gilead, HIV, pharma
Gilead has lifted the curtain on new preclinical data on the efficacy of a combo therapy of GS-9620, its investigational …
FDA finds major manufacturing issues at key Aurobindo facility
March 5, 2018Manufacturing and Production, Sales and Marketing Aurobindo, FDA, pharma
Indian pharmaceutical firm Aurobindo has been rocked by an USFDA review which identified nine major issues with its Unit 4 …
Celgene strikes $101m partnership in oncology, neurodegenerative and inflammatory
March 5, 2018Research and Development, Sales and Marketing Cancer, Celgene, Vividion, inflammatory, neurodegenerative, oncology, pharma
Celgene has inked a new multi-year partnership with biotech firm Vividion Therapeutics to leverage the latter’s proteomics and chemistry platforms …
NHS trials “world-leading” initiative to cut prostate cancer diagnoses to just days
March 5, 2018Research and Development, Sales and Marketing Cancer, MRI, NHS, pharma, prostate cancer
The NHS has revealed plans to cut the average diagnosis times for prostate cancer from six weeks to less than …
Abbvie and Biogen pull MS drug Zinbryta following urgent EMA safety review
March 5, 2018Sales and Marketing AQbbvie, Biogen, EMA, Europe, mulyiple sclerosis, pharma, zinbryta
Biogen and Abbvie have announced their intention to voluntarily withdraw their multiple sclerosis therapy Zinbryta (daclizumab) from all global markets …
Top Ten most popular articles on Pharmafile.com this week
March 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines
We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …
Endo granted injunction to block blood pressure competitor
March 2, 2018Medical Communications, Sales and Marketing Endo, QuVa, Vasostrict, blood pressure, pharma, vasopressin
Generics and speciality pharma firm Endo International has revealed that it has been granted a preliminary injunction to block competitor …
Study identifies five kinds of diabetes, potentially changing treatment
March 2, 2018Medical Communications, Research and Development biotech, diabetes, drugs, pharma, pharmaceutical
A decade-long study has unearthed findings that could entirely change how people living with diabetes are treated, after the classic …
Artificial Cell Technologies CFO accused of stealing nearly $1m in company funds
March 2, 2018Medical Communications, Sales and Marketing Artificial Cell Technologies, cfo, pharma
A high-ranking C-level executive of a US biotech start-up has been charged with embezzling almost $1 million from the company …
Novartis forms a Pear to develop mobile therapies
March 2, 2018Medical Communications, Research and Development Novartis, Pear Therapeutics, biotech, drugs, pharma, pharmaceutical
Novartis has announced an agreement between Pear Therapeutics and itself to develop two digital therapeutics, one in schizophrenia and one …
Ipsen: Becoming a “development powerhouse”
March 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing David Meek, Insider Interview, ipsen, pharma
Immediately following the release of impressive full year financials, Ipsen CEO David Meek speaks on how the company is hitting …
Takeda to create 70 jobs with €25m Dublin investment
March 1, 2018Manufacturing and Production Dublin, Takeda, pharma
Takeda has announced its investment of €25 million to construct a new “modular cell therapy facility dedicated to manufacturing a …
Merck/Pfizer’s Bavencio wins slight reprieve after NICE nod
March 1, 2018Medical Communications, Sales and Marketing Bavencio, Merck, Pfizer, biotech, drugs, pharma, pharmaceutical
Just two weeks ago, Merck KGaA and Pfizer were hit with a major setback for their PD-L1 immunotherapy, Bavencio, after …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
